This is best exemplified by the synthetic lethal use of poly (ADP-ribose) polymerase-1/2 inhibitors (PARPi) to treat high-grade serous carcinomas that harbour a BRCA1 or BRCA2 pathogenic/likely pathogenic variant [4]. This evidence concerns the gene BRCA1 and serous adenocarcinoma.